Reader TTS

ABSTRACT Muscle regeneration is a physiological process that converts satellite cells into mature myotubes under the influence of an inflammatory environment progressively replaced by an

anti-inflammatory environment, with precise crosstalk between immune and muscular cells. If the succession of these phases is disturbed, the immune system can sometimes become auto-reactive,

leading to chronic muscular inflammatory diseases, such as myositis. The triggers of these autoimmune myopathies remain mostly unknown, but the main mechanisms of pathogenesis are partially

understood. They involve chronic inflammation, which could be associated with an auto-reactive immune response, and gradually with a decrease in the regenerative capacities of the muscle,

leading to its degeneration, fibrosis and vascular architecture deterioration. Immunosuppressive treatments can block the first part of the process, but sometimes muscle remains weakened, or

even still deteriorates, due to the exhaustion of its capacities. For patients refractory to immunosuppressive therapies, mesenchymal stem cells have shown interesting effects but their use

is limited by their availability. Stromal vascular fraction, which can easily be extracted from adipose tissue, has shown good tolerance and possible therapeutic benefits in several

degenerative and autoimmune diseases. However, despite the increasing use of stromal vascular fraction, the therapeutically active components within this heterogeneous cellular product are

ill-defined and the mechanisms by which this therapy might be active remain insufficiently understood. We review herein the current knowledge on the mechanisms of action of stromal vascular

fraction and hypothesise on how it could potentially respond to some of the unmet treatment needs of refractory myositis. SIMILAR CONTENT BEING VIEWED BY OTHERS REGULATORY T CELLS IN

SKELETAL MUSCLE REPAIR AND REGENERATION: RECENT INSIGHTS Article Open access 05 August 2022 NON-MYOGENIC MESENCHYMAL CELLS CONTRIBUTE TO MUSCLE DEGENERATION IN FACIOSCAPULOHUMERAL MUSCULAR

DYSTROPHY PATIENTS Article Open access 16 September 2022 ADIPOSE TISSUE IS A SOURCE OF REGENERATIVE CELLS THAT AUGMENT THE REPAIR OF SKELETAL MUSCLE AFTER INJURY Article Open access 05

January 2023 FACTS * Muscle regeneration involves a sequence of tissue repair mechanisms regulated by both pro- and anti-inflammatory immune cells. * Myositis pathomechanisms are not fully

understood but may result from chronic exposure to immune cells and cytokines, leading to destruction and mis-repair of muscle, with fibrosis and vascular architecture disturbance. *

Therapeutic options for inflammatory myopathies are predominantly based on immunosuppressive treatments, which are sometimes insufficient to regulate the different features of these complex

pathologies. * Adipose tissue-derived stem cells and stromal vascular fraction have immunomodulatory, anti-fibrotic, proangiogenic and regenerative properties that could be exploited for the

treatment of refractory or relapsed myositis. * However, the mechanisms behind these effects are still insufficiently understood and more preclinical studies are required before their

clinical use. OPEN QUESTIONS * Does repeated acute muscular destruction trigger chronical autoimmune inflammation, or is auto-immunity responsible for muscle destruction in myositis? * In

myositis, how does chronicle inflammation affect adipose-derived cells capacities? * Will adipose stem cells replace muscle stem cells and directly participate in tissue regeneration, or

rather have a supporting role for immune and local stem cells? INTRODUCTION The mechanisms of muscle regeneration following injury are now well-known and involve both muscle and immune

cells, through a regulated process [1]. A disruption of this process may be the cause of chronic inflammation and a failure of muscle regeneration, which can lead to autoimmune diseases such

as myositis. Myositis, also called idiopathic inflammatory myopathies, represents a group of immune-mediated diseases, including Polymyositis (PM), Dermatomyositis (DM), Immune-Mediated

Necrotising Myositis (IMNM), Inclusion Body Myositis (IBM) and overlap myositis [2]. They are clinically characterised by muscle weakness, and histologically by the presence of varying

levels of myofibre necrosis and leucocyte infiltrates in muscles [3]. Predominantly muscular, some forms of myositis can also be associated with other manifestations, such as Interstitial

Lung Disease (ILD), skin ulcers or Raynaud’s phenomenon. Corticosteroids and immunosuppressive drugs are commonly used but may be ineffective in some patients or even aggravating due to

their possible side effects [4,5,6]. For these patients, cell therapies have sometimes shown long-term beneficial effects. Autologous hematopoietic stem cell transplants, which have been

used to replace auto-reactive immune systems, have improved patients’ conditions, and even allowed some of them to enter into remission. These therapies generally seem to be safe, but can be

complicated by severe or even life-threatening iatrogenic infections due to myeloablative conditioning regimens [7,8,9,10]. More recently, the discovery of the immunomodulatory effects of

Mesenchymal Stem Cells (MSC) from Bone Marrow (BM-MSC) or Umbilical Cord Blood (UC-MSC), in addition to their well-known regenerative effect, has led to their use for the treatment of

patients with refractory autoimmune diseases, including myositis [11]. If these types of stem cells seem safer, the invasiveness of the harvesting and the low rate of stem cells recovered

from these sources remain important limitations to their use. Adipose tissue is another source of MSC. They can be extracted safely and in large quantities from a lipoaspirate by enzymatic

digestion or mechanical isolation for Stromal Vascular Fraction (SVF), followed by replicative cultures of adherent cells for Adipose-Derived Stem Cells (ADSC) [12]. If ADSC are known to

possess immunomodulatory, proangiogenic, anti-fibrotic and regenerative capacities like MSC from other tissues [13], SVF share similar properties and is easier to prepare [14]. However, the

therapeutically active components within this heterogeneous cellular product are not well defined, and the mechanisms responsible for its activity remain insufficiently understood. In order

to evaluate the potential of SVF as a treatment for refractory myositis, we first summarise here the physiological mechanisms of muscle regeneration and the pathological mechanisms involved

in myositis. Next, we address the main features of these diseases through the known mechanisms of action of this cell therapy. Last, we discuss its clinical relevance by analysing results

from various clinical trials. PHYSIOLOGICAL MUSCLE REGENERATION Muscle regeneration after trauma is a process that involves both immune and muscular cells in order to restore normal muscle

function. At first, satellite cell activation and proliferation accompanied by inflammation, followed by a progressive decrease of inflammation under the influence of anti-inflammatory

cells, which stimulate muscle progenitor cell differentiation and tissue remodelling [15]. At the earliest stage of regeneration after injury, muscle damaged cells release Damage-Associated

Molecular Patterns (DAMP) [16], which lead through Toll Like Receptor (TLR) to the activation and infiltration of immune cells, mostly mast cells [17] and neutrophils [18]. These cells start

to clear the damaged myofibres and secrete pro-inflammatory cytokines (mostly IL-1, IL-6, IL-8 and TNFα). The pro-inflammatory signal spreads and after 24 h, macrophages can be observed at

the lesion site [19]. They are mostly involved in the elimination of damaged muscular cells by the production of Reactive Oxygen Species (ROS), through the increased expression of Inducible

Nitric Oxide Synthase (iNOS), and phagocytosis. Like neutrophils, they secrete a large amount of cytokines (mostly TNFα, IL-6, and IL-1β) which triggers a positive feedback loop between

neutrophil and macrophage recruitment and production of cytotoxic substances, but also T-cell recruitment [20]. Around three days after injury, both CD8+ and CD4+ T cells appear at the

lesion site and can be detected for up to ten days [21]. CD8+ T cells pursue the task of macrophages and neutrophils, by releasing many cytokines which amplify the recruitment of leucocytes

and by acting on extracellular matrix remodelling to speed up cellular debris elimination [22]. CD4+ T cells seem to be recruited a little later than CD8+ T cells [23]. They differentiate

preferentially into Th1 cells, which maintain macrophage recruitment and pro-inflammatory polarisation through the production of cytokines (IL-1β, TNFα and IFNγ). The large amount of

secreted cytokines modulates the environment of the injured site and triggers muscular regeneration [1]. Fu et al. demonstrated that the cytokines secreted by T cells promote satellite cell

proliferation in vitro and in vivo [24]. Indeed, TNFα is known to attract satellite cells to the damaged site and to enhance their proliferation through the activation of NF-κB signalling

and the p38 pathway [25, 26]. The importance of TNFα secretion in response to muscular damage has been demonstrated in vivo in TNFα or TNF-receptor knockout mice, which show severe muscular

regeneration defects [27, 28]. TNFα is associated with other cytokines, such as IL-6, secreted by both immune and muscle cells, and IL-1β, which maintains the proliferation but also

stimulates the differentiation of satellite cells into myoblasts [29, 30]. The importance of IL-1β has also been demonstrated in IL-1β knockout mice, which present a slowdown of satellite

cell differentiation, shown by a reduced expression of myoblast markers MyoD and Myogenin. When the clearing of damaged cells ends, the naive T cells recruited polarise into Th2 cells, which

release anti-inflammatory cytokines (IL-4 and IL-13) [31]. These cytokines stimulate myoblast fusion and Fibro–Adipogenic Progenitor (FAP) proliferation [32]. After activation and

differentiation, FAP are another source of myogenic factor like Wnt family members, IL-6 and Insulin-like Grow-Factor 1 (IGF1), which enhance satellite cell proliferation and myoblast

differentiation and fusion [33,34,35]. They also release IL-33, which participates in the activation of muscle Treg cells and the recruitment of circulatory Treg cells, which are genetically

and functionally distinct [36]. Indeed, in addition to regulating and reducing the inflammatory environment, muscle Treg cells play an important role in regeneration through amphiregulin

secretion [37, 38]. The change of inflammatory environment is mainly based on the change of macrophage populations from pro-inflammatory to anti-inflammatory, under the influence of Th2 and

Treg cell cytokines [39]. These macrophages produce anti-inflammatory cytokines (IL-4, IL-10 and IL-13), which reduce the local inflammation induced by the lesion and stimulate the

differentiation and fusion of myoblasts into myotubes, promoting the late stage of myogenesis [35, 40]. They also release TGFβ, which regulates myotube fusion and prevents the TNFα-induced

apoptosis of FAP, inducing their differentiation into matrix-producing cells [41]. These cells also produce growth factors such as IGF1, Hepatocyte Growth Factor (HGF), basic Fibroblast

Growth Factor (bFGF), and Vascular Endothelial Growth Factor (VEGF), which stimulate endothelial cells and contribute to bringing together endothelial and satellite cells [42]. The proximity

and crosstalk between muscular, mesenchymal and endothelial cells are essential for both myoangiogenesis and total muscle recovery [43]. DEFECTIVE MUSCLE REGENERATION DURING MYOSITIS The

myoregeneration process relies on the presence of functional satellite cells in the muscle and the environmental agents that control at different phases the proliferation, differentiation

and fusion of these cells into myotubes [44]. Among these stimuli, secretion by immune cells of pro- then anti-inflammatory cytokines plays an important role. In the case of myositis, a

chronic activation of innate and adaptive immune cells which can recognise auto-antigens is observed and these cells, normally transient, remain in the muscle (Fig. 1). Neutrophil

persistence in muscle infiltrates has been demonstrated in myositis muscle, as well as neutrophil participation in the destruction of muscle fibres through the release of proteolytic enzymes

and the formation of neutrophil extracellular traps [45, 46]. Further, this extracellular formation seems to be induced by the presence of myositis-associated antibodies. Reimann et al.

showed an increase in pro-inflammatory macrophage density in muscle, through iNOS expression correlated with a high expression of macrophage migration inhibitory factor, a cytokine with

anti-apoptotic, proliferative and chemotactic effects secreted by macrophages, T cells and muscle fibres [47]. Myositis patients present a strong Th1 response, with an increased expression

of IFNγ, IL-1β and TNFα [48, 49]. This Th1 response leads to the induction and maintenance of pro-inflammatory macrophages and thus amplifies muscle destruction [50]. A type 1 IFN signature

was observed in the blood of patients with DM or PM and correlated with disease activity [51]. A recent study showed that the activation of type 1 IFN pathway in muscle cells in vitro

induced myotube atrophy and impaired endothelial cell angiogenesis, features that were observed in DM [52]. Muscle destruction is also due to the abnormal expression of Major

Histocompatibility Complex type I (MHC-I) on the myocyte surface, induced by IFNγ and IL-1β [53]. This expression is also induced by IL-17, produced by Th17 cells, which potentiates the

effects of IL-1β. Some studies have shown that overexpression of MHC-I in muscle can induce myopathy through both immunological, with CD8+-mediated cytotoxicity, and nonimmunological

mechanisms [54, 55]. Thereby, both CD4+ and CD8+ T cells can be activated by muscle cells, which act directly as antigen presenting cells, but also indirectly through dendritic cells (DC)

detected in muscular infiltrate during myositis [56], or TLR stimulation by DAMP [16, 57]. The activation and differentiation of T cells by these cells lead to the formation of a permissive

environment for B-cell maturation, evidenced by the presence of CD19+ or CD20+ B cells and CD138+ plasma cells and by the expression of B-cell activating factor [58]. Myositis specific

antibodies were identified in more than half of patients [2], and a recent study associated Th1 and Th17 cytokine expression with B-cell aggregation and maturation, through the formation of

ectopic lymphoid structures in myositis muscle [59]. The pathogenicity of these antibodies has not always been demonstrated, however they are often correlated with the severity of the

myositis and the underlying diseases, like ILD, Raynaud syndrome or cancer [60]. Furthermore for some of them, the mechanism of action has been identified, notably in IMNM, wherein

anti-3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and anti-signal recognition protein (SRP) induce myofibre atrophy by increasing IL-6, TNFα and ROS secretion. They also reduce myotube

formation by decreasing IL-4 and IL-13 production [61]. This pathogenic effect seems also to involve complement system [62]. Anti-inflammatory cells are also present in myositis muscle and

some of them take part in the pathomechanism. If the Th2 cytokine IL-4 overexpressed in myositis seems inversely correlated with the severity of muscular destruction, as evidenced by

muscular enzyme levels in the sera [63], anti-inflammatory macrophage cytokines (TGFβ and IL-10) are also highly expressed in myositis and seem to be involved in the pathogenesis [47, 64].

Prolonged exposure to TGFβ and IL-10 is correlated with the duration of myositis via their association with other cytokines, especially in IBM [50, 65]. Prolonged TGFβ1 exposure, for

example, is strongly involved in the dysregulation of muscle regeneration in different myopathies, by inhibiting satellite cell activation and differentiation and myocyte fusion, but also by

increasing myofibroblast accumulation and fibrosis [66,67,68]. Muscle fibrosis is also generated by the accumulation of FAP, which escape TNF-induced apoptosis and differentiate into

collagen type-1 producing cells (fibroblasts) under TGFβ1 high expression by anti-inflammatory macrophages [41, 69]. This escape from apoptosis could also be due to the expression of immune

checkpoint factors (PD-L1, PD-L2 and CD47) by FAP, as shown in a murine model of myositis [70]. Fibrosis can lead, like in IBM, to tissue and capillary architecture disruption and to an

increased distance between muscle fibres and capillaries, responsible for hypoxia and oxidative stress [71]. Treg cell functions are also altered in myositis, which leads to the

dysregulation of immune response and to the impairment of muscle regeneration. Indeed, Treg dysfunctions have been evidenced in both DM and PM and in several myositis models, which present a

more severe disease when Treg cells are depleted. Conversely, the injection of functional Treg cells at the time of immunisation blocked disease progression [72]. On the other hand, Treg

cells seem to be fully functional in IBM despite a decreased frequency observed in circulation and muscle [49]. If the pathogenic triggers of myositis have not yet been identified, partially

due to a lack of spontaneous animal models, the hypothesis of an immune system defect which is solely responsible or even at the origin of the disease is controversial, especially in IBM

[73, 74]. Muscle cells participate in the pathogenesis and aggravation of the disease, through the activation of several deleterious and not fully understood mechanisms, involving

endoplasmic reticulum and/or mitochondrial defects. If MHC-I expression on muscle cell surface is often linked to leucocyte infiltration, it has been shown that it can be induced by

endoplasmic reticulum stress, and that its presence can be detected before infiltrate and can affect muscle fibre contractibility [75]. Beyond muscle destruction, which stays chronically

blocked in pro- and/or anti-inflammatory state without resolution, the impairment of satellite cell capacities to activate and proliferate is also involved in the disease. Myoblasts from IBM

patients also present reduced proliferation rate and clonogenicity capacity in vitro when compared to myoblasts from healthy donors, probably due to replicative exhaustion and senescence

[76]. This observation was confirmed in vivo, with a lower expression of MyoD [71]. Moreover, the persistence of myogenin expression observed in these patients might reflect an impairment of

both myoblast differentiation and muscle fibre maturation. Myositis represents a heterogeneous group of diseases which involve immune and non-immune mechanisms. In these diseases, the

immune system acts on both muscle degeneration and regeneration, with muscle progenitor cell stimulation by cytokines. While suppressing myositis may appear as an effective solution to stop

or to slow down the disease, this can be insufficient or even aggravating sometimes, due to non-immune mechanisms or regenerative defects. CURRENT THERAPEUTICS FOR MYOSITIS PATIENTS Most of

the treatments used in myositis target the inflammatory actors. Glucocorticoids are the most current therapeutic approach, alone as a first-line treatment or associated with other

immunosuppressive molecules in refractory patients [77]. These associations are more efficient to improve muscle function, and act on myositis-associated diseases like ILD. Moreover, they

allow to reduce the corticosteroid effective dose, leading to fewer side effects, especially on muscle [78]. Nevertheless, the use of immunosuppressive molecules is also limited by their own

adverse effects, including toxicities on various organs (liver, lung, kidney, heart), risk of infection and metabolic disorders (diabetes, dyslipidemia) [79]. These various side effects are

even more problematic in elderly subjects who suffer from numerous co-morbidities. Biological agents have also been tested in myositis: at first, Intravenous (IV) immunoglobulins,

considered to present immunomodulatory properties, and then monoclonal antibodies, such as Rituximab (anti-CD20), Tocilizumab (anti-IL-6), Infliximab (anti-TNFα), Alemtuzumab (anti-CD52),

Basiliximab (anti-IL-2R) or Sifalimumab (anti-IFNα), or even receptor antagonist Anakinra (anti-IL-1R), JAK inhibitor Tofacitinib and fusion proteins Abatacept or Etanercept, which block

CTLA-4 or TNFα pathways, respectively [6, 80, 81]. If these treatments are efficient in most of first- and second-lines refractory to DM and PM, some patients stay refractory or relapse to

all of them. Complement inhibition has also been tested in IMNM, with a preventive effect in animals but no significant improvement in management in humans [82, 83]. Further, these

treatments seem to bring no benefit and even to exacerbate the disease in IBM patients, who remain in a therapeutic deadlock [4]. In this myositis subtype, new molecules are under

evaluation, like Arimoclomol, a Heat Shock Factor 1 activation amplificator, which increases chaperone protein activity and thus misfolding protein repair pathway, or follistatin, a

myostatin antagonist, with an adeno-associated virus coding for it injected Intramuscularly (IM) [84]. New monoclonal antibodies targeting myostatin or activin A, which both negatively

regulate myogenesis, have been developed but clinical trials in IBM have been recently withdrawn or cancelled for these treatments [85]. Cell therapies are occasionally used to treat

patients with refractory PM or DM, but very few cases have been reported. As stated above, hematopoietic stem cell autologous transplantation, used to replace auto-reactive immune system

after its depletion, has shown benefits but with a high risk of side effects [7,8,9,10]. MSC transplantations, for which no myeloablative treatment is required, have also been tested (Table

1). The first clinical study using MSC was published in 2011 by Wang et al. and reported the case of 10 patients with refractory PM or DM, according to Bohan and Peter criteria [86]. After

treatment by IV allogeneic BM- or UC-MSC, they observed an improvement in muscle strength and clinical score and a reduction of inflammation and muscle degeneration [87]. Transplanted cells

were also effective on associated symptoms, notably ILD and skin ulcer, and allowed the reduction of immunosuppressive baseline treatments for all patients. However, three patients relapsed

and two patients died from aggravation of a respiratory tract infection. This cohort was followed-up and has grown overtime to thirty patients and safety data were published in 2018. They

showed a low frequency of hyperacute adverse events, but reported the death of 11 patients from their underlying diseases, mostly ILD [11]. Lai et al. published the only controlled clinical

trial, comparing conventional therapy (6 months of corticosteroids and immunosuppressors) with (_n_ = 37 patients) or without (_n_ = 44 patients) allogeneic UC-MSC injections in patients

with PM or DM [88]. After a follow-up of 6–12 months, the authors demonstrated an improved efficacy of conventional therapy by MSC infusion on both clinical features and muscle strength (MMT

score), confirmed by a decrease in plasma creatine kinase level. They also showed an effect on associated ILD, with a reduction of interstitial pulmonary lesions on high resolution CT scan.

Clinical and biological controls at 1, 3 and 6 months after transplantation did not reveal any complications. Only one study reported the case of a patient with refractory and disabling PM

treated by four ADSC infusions, leading to an improvement in muscle strength (MMT score) and mobility 3 months after treatment, but no significant change in blood laboratory values [89]. The

patient continued corticosteroid treatment at a lower dose. Pharmaceutical and biological treatments have evolved and now allow to treat most of patients with myositis. After multiple lines

and associations of treatment, some patients with PM or DM remain refractory and more often those with IBM. In the latter case, new treatments under evaluation target more specifically

muscle degeneration, through metabolic or regulatory pathways, but the expected effect is not always obtained. Conversely, MSC therapies have shown interesting results in myositis, but their

harvest and preparation are not simple and clinical studies remain rare. SVF, which has similar effects, could be an alternative, provided its clinical efficacy is proved through robust

clinical trials. Two of them are about to start to study the safety of SVF in IBM (NCT04975841, NCT05032131). STROMAL VASCULAR FRACTION IN CLINICAL PRACTICE SVF isolation consists in

adipocyte elimination through enzymatic or mechanical procedures [90, 91]. Due to the variety of isolation methods, the International Federation for Adipose Therapeutics and Science (IFATS)

and the International Society for Cellular Therapy (ISCT) have released a joint statement that defines phenotypic and functional criteria for the identification of adipose-derived cells, and

proposes a general composition for SVF [12]: MSC (15–30%), Endothelial Progenitor Cells (EPC) (10–20%), Pericytes (3–5%) and leucocytes (25–45%) (Fig. 2A). According to the SVF isolation

method used, two types of SVF can be defined: cellular SVF, which can be obtained by enzymatic procedure, and tissular SVF, which is mechanically isolated and preserves cell-cell contact and

extracellular matrix [92, 93]. Recently, another intermediate type has been described: adipose-derived microvascular fraction which consists in lipoaspirate cells enzymatically digested for

a shorter time than cellular SVF, and which contains intact arteriolar, capillary and venous vessel segments [94]. Today, SVF is widely used and frequently compared to ADSC in both

regenerative medicine and immune/inflammatory disorders and presents significant advantages. Indeed, SVF extraction is simpler and quicker than ADSC expansion and does not present the risks

associated with long-term cell culture (bacterial or fungal contaminations, muta- or tumorigenesis). Combined with a permissive regulatory framework in some countries, the use of SVF has

regrettably been diverted by private clinics with little interest in studying the efficacy and mechanisms of action of this therapy, which has slowed its development. This was particularly

observed in the United States, which had an unusually low number of publications on the topic [95] whereas a very large number of clinics offer these unproven therapies [96, 97]. However,

this situation is about to change, with the end of the Food and Drug Administration discretion policy period which should enforce manufacturers, clinics, and health care practitioners

compliance with the new guidance on the regulatory framework for regenerative medicine therapies and ensure a greater safety for the use of these therapies [98]. The use of SVF has been

reported in many indications and it may represent a promising adjunctive therapy for patients with diseases for which current and conventional therapies are inadequate. The variety of these

indications was recently reviewed by Andia et al. who analysed 71 published clinical studies evaluating SVF [99]. However, more than 65% of them were case series with a low level of

evidence, and only 16% of them were randomised clinical trials. To confirm this analysis, we searched for clinical trials on clinicaltrial.gov database in May 2023 (search strategy with the

key words: Stromal vascular fraction OR SVF OR ADSVF OR ADRC OR ADSC), which allowed us to identify 169 clinical trials evaluating SVF injection (Fig. 2B). The most common indications,

according to these studies, were orthopaedic disorders (50.7% and 28.9% for published studies and clinical trials, respectively), then chronic wounds (14% and 24.1%) and cardiovascular and

pulmonary diseases (12.6% and 13.9%) (Fig. 2B). Other frequent indications were urogenital (5.6% and 9.6%), neurological (5.6% and 4.8%), and autoimmune diseases (5.6% and 11%), which often

overlapped with chronic wound treatment. These data are consistent with those from other studies [14, 99] and demonstrate the increasing interest of SVF for the treatment of inflammatory,

degenerative or non-regenerative, autoimmune or cardiovascular diseases. Local sites of injection were more frequent than intravascular, with a predominance of sub-cutaneous,

intra-articular, intra-fistula and intramuscular injection (Fig. 2D). Nevertheless, SVF is still a new therapy under development and clinical trials were mostly pilot studies in phase I (73%

versus 32.9% for all clinical trials), and phase II and III appeared only recently (23% versus 42.4% and 4% versus 24.7%, respectively) (Fig. 2E). Furthermore, several SVF clinical trials

were not completed (39% versus 15%), closed prematurely or withdrawn (23.3% versus 4.3%) (Fig. 2F). None of these closures were due to a safety issue. Some recent studies reviewed adverse

events in patients receiving “unproven or unapproved” stem cell therapies reported in scientific publications, clinical case reports and also mass media publications, and showed an increased

number of severe complications and hospitalisations compared to conventional therapies [100, 101]. Conversely, very few treatment‐related adverse events were noted during clinical trials,

demonstrating the safety of this procedure. Recently, clinical study results published for both SVF and ADSC were reviewed and showed that the most frequent and severe adverse events were

immunological and thromboembolic. They concerned predominantly ADSC, which were more frequently used in an allogeneic context and via IV injection than SVF [95]. Indeed, the in vitro

expansion of ADSC led to an increase in cell size, which significantly increased the risk of vascular obstruction and cerebral or myocardial stroke [102]. The injection of SVF directly at

the lesion site or within organs seems to be a safer way to use this therapy. Intramuscular injections of SVF were clinically used as a local route for the treatment of muscle sequelae [103,

104], allowing an improvement in muscle strength, or for the treatment of limb ischaemia [105, 106], highlighting its proangiogenic effects. In these studies, the safety of this route was

confirmed. Furthermore, IM injection led to the release of paracrine effectors in blood circulation and could be an alternative to other injection sites (intrathecal, intra-articular) [107].

Another advantage of this route was the increased dwell time of the injected cells, increasing from days to months the persistence in the body of these cells [108]. Even if they remained in

the muscle, they still responded to distant inflammatory signals and acted on distant sites [109]. IM injection of SVF could lead to prolonged clinical efficacy compared to other routes, in

both injected and non-injected muscles. POTENTIAL MECHANISMS OF ACTION OF STROMAL VASCULAR FRACTION IN MYOSITIS As seen above, intramuscular injection of SVF is known to be safe and has

promising clinical effects in both autoimmune and muscular diseases. Its potential interest in myositis treatment is based on four properties, but mechanisms of action are not fully known

(Fig. 3). First, the immunomodulatory effect of SVF is supported mainly by three cell populations: AD-MSC, macrophages and Treg cells. AD-MSC immunomodulatory capacities are similar or

higher to those of BM-MSC according to different studies [110, 111] and have already been tested in vitro [112] and in many in vivo models [113]. Even if the mechanisms involved are not

fully understood for these cells, several studies support their effects on T-cell activation, proliferation and differentiation from Th1 cells into Th2 cells, through soluble factors like

PGE2 and IDO [114,115,116] and direct interactions via CD54/CD2 and CD58/CD11a, which increase IL-10 production [117]. They also induce Treg proliferation, via TGFβ and IL-33 secretion [118,

119], and few adipose tissue Tregs are present in SVF. MSC also act on macrophage anti-inflammatory switch, in part by the secretion of PGE2 and IDO [120] and the interaction of CD90 and

CD11b trapping monocytes and macrophages into an anti-inflammatory niche [121]. Recent studies have shown that the interactions between MSC and pro-inflammatory cells enhance the

immunosuppressive capacities of MSC. Indeed, these authors observed that IFNγ and TNFα secreted by Th1 lymphocytes or CD54 expressed by pro-inflammatory macrophages increased IDO activities

[122, 123]. SVF also contains macrophages which exhibit anti-inflammatory activities through the secretion of high levels of IL-10 and IL-1 decoy receptors [124] that attenuate TNFα

inflammatory signals via activation of STAT3 [125, 126], and modulation of inflammatory gene transcription rates [127]. The modification of the balance between Arg-1 and iNOS activities,

which both use L-arginine as a substrate, leads to decreased ROS production, and thus to reduced oxidative stress and destruction of myofibres. ADSC and SVF can also act on fibrosis via

their immunomodulatory effects. Indeed, by reprogramming immune cells into anti-inflammatory cells, they increase the expression of IL-10, which presents several anti-fibrotic properties:

inhibition of neutrophil and macrophage invasion and ROS release [128], down-regulation of TGFβ1 expression [129], up-regulation of MMP and down-regulation of collagen expression [130].

Preclinical and clinical studies suggest that SVF anti-fibrotic effects are strongly related to the secretion of HGF by MSC during inflammatory responses, as evidenced by clinical and

histological parameters [131, 132]. Indeed, through the paracrine effect of this factor, SVF and ADSC reduce the expression of TGFβ1 and thus the differentiation of collagen type I/III

producing cells (fibroblasts) and alpha-Smooth Muscle Actin producing cells (myofibroblasts). ADSC also induce a significant increase in TGFβ3, which reduces the expression of these genes,

and stimulates MMP-1, -2 and -3 expressions, which increase fibrotic molecule degradation. The change in the TGFβ1/TGFβ3 and MMP-2/TIMP-2 ratio tips the scales in favour of an anti-fibrotic

effect [133, 134]. MMP expression is also stimulated by proangiogenic factors, like bFGF or VEGF, to degrade extracellular matrix and prepare neo-angiogenesis [135]. Indeed, SVF is known to

express high levels of IGF1, IL-8, Platelet-Derived Growth Factor-beta (PDGFβ), bFGF and VEGF, and to have robust angiogenic and vasculogenic activities demonstrated both in vitro and in

vivo in a hind limb ischaemia model [136]. These growth factors help to maintain a vascular-like micro-environment that supports MSC differentiation into endothelial cells, and thus

participate in angiogenesis and vascular repair during muscular regeneration [137]. Traktuev et al. demonstrated that VEGF helps the migration of MSC and promotes the secretion of PDGFβ by

EPC, which enable MSC to proliferate [138, 139]. PDGFβ is well-known for its action during vascular development [140] but also plays a role in the proangiogenic properties of SVF, by

inducing the secretion of proangiogenic extracellular vesicles by both MSC and EPC [141, 142]. These extracellular vesicles contain proangiogenic molecules such as c-KIT and Stem cell

factor, which participate in the recruitment of EPC and their differentiation into endothelial cells [143]. PDGFβ secretion by EPC also induces pericyte recruitment [144] which is known to

play an essential role in angiogenesis regulation [145]. SVF, through its immunomodulatory properties, acts on both chronic inflammation and muscle repair via cytokine release (mainly IL-4

and IL-13). Moreover, growth factors secreted by stromal cells may have a positive effect on muscle regeneration, and some of them are currently under evaluation in the management of muscle

disorders, such as sarcopenia [146]. But one advantage to using cell therapy, rather than hormones or cytokines, could be its ability to differentiate in situ depending on its cellular

environment. This could strengthen and help satellite cells to replace defective cells. The conversion of ADSC or SVF to a myogenic phenotype has been obtained in vitro by addition of

inductive media, containing horse serum and hydrocortisone. This leads to the expression of the myogenic transcription factors Myod1 and myogenin and then the fusion and formation of

multinucleated cells expressing the myosin heavy chain [147,148,149]. Based on histological evidence, ADSC fuse to form multinucleated myotubes in vitro. In their study, Di Rocco et al.

showed that ADSC and SVF cells were able to differentiate into skeletal muscle cells when cultured in the presence of differentiating primary myoblasts [150]. Furthermore, the conversion of

SVF to a myogenic phenotype is enhanced by myogenic environment in the absence of cell-cell contacts (transwell culture) and even in absence of muscle cells but to a lesser extent. This

myogenic conversion has also been demonstrated in vivo by several studies. In a lagomorphic model of muscular injury induced by cardiotoxin, the intramuscular injection of short-term

cultured (3 days) SVF cells induced an increase in muscle mass and functional capacities [151]. The myogenic differentiation of SVF and fusion with muscular cells have been demonstrated

using SVF genetically modified to express β-galactosidase or GFP, showing evidence of the contribution of SVF cells to muscular regeneration in vivo with 20% of GFP-positive fibres in the

total area of sections from treated hind limbs [150, 151]. This contribution could be enhanced by pretreating SVF with anti-inflammatory cytokine IL-4 or SDF1 before use to increase the

myogenic capacity of ADSC in vitro and in vivo [152]. To finish, it has also been reported that injection of human ADSC into immunocompetent mdx mice resulted in a substantial expression of

human dystrophin in both injected and adjacent muscle, revealing the spread of cells to other muscles [153]. CONCLUSION MSC-based therapies have shown interesting effects in the treatment of

refractory myositis, but their clinical use remains limited, especially for those extracted from adipose tissue. However, SVF, easily harvested from this tissue, could be beneficial for

patients thanks to its properties combining an immunomodulatory effect and a response to the main muscular complications of myositis. While published cases report only IV infusion of MSC in

myositis treatment, IM injection of SVF seems to be an interesting alternative, providing both local and systemic effects. Taken together, the evidence reviewed here seems to predict a

potential benefit of SVF in myositis treatment. However, these findings also highlight the need for preclinical studies and clinical trials to better understand the mechanisms of this

therapy and to optimise the practical modalities to ensure its safety and efficacy. REFERENCES * Yang W, Hu P. Skeletal muscle regeneration is modulated by inflammation. J Orthop Transl.

2018;13:25–32. Google Scholar  * Allenbach Y, Benveniste O, Goebel H-H, Stenzel W. Integrated classification of inflammatory myopathies. Neuropathol Appl Neurobiol. 2017;43:62–81. CAS 

PubMed  Google Scholar  * Meyer A, Lannes B, Goetz J, Echaniz-Laguna A, Lipsker D, Arnaud L, et al. Inflammatory myopathies: a new landscape. Jt Bone Spine. 2018;85:23–33. CAS  Google

Scholar  * Benveniste O, Guiguet M, Freebody J, Dubourg O, Squier W, Maisonobe T, et al. Long-term observational study of sporadic inclusion body myositis. Brain J Neurol. 2011;134:3176–84.

Google Scholar  * Jabari D, Vedanarayanan VV, Barohn RJ, Dimachkie MM. Update on inclusion body myositis. Curr Rheumatol Rep. 2018;20:52. PubMed  Google Scholar  * Oddis CV, Aggarwal R.

Treatment in myositis. Nat Rev Rheumatol. 2018;14:279–89. CAS  PubMed  Google Scholar  * Baron F, Ribbens C, Kaye O, Fillet G, Malaise M, Beguin Y. Effective treatment of Jo-1-associated

polymyositis with T-cell-depleted autologous peripheral blood stem cell transplantation. Br J Haematol. 2000;110:339–42. CAS  PubMed  Google Scholar  * Zhu J, Su G, Lai J, Dong B, Kang M, Li

S, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for refractory juvenile dermatomyositis: a case-series study. Pediatr Rheumatol. 2018;16:72. Google

Scholar  * Henes JC, Heinzelmann F, Wacker A, Seelig HP, Klein R, Bornemann A, et al. Antisignal recognition particle-positive polymyositis successfully treated with myeloablative autologous

stem cell transplantation. Ann Rheum Dis. 2009;68:447–8. CAS  PubMed  Google Scholar  * Salvador FB, Isenberg DA. Use of autologous stem cell transplantation in adult patients with

idiopathic inflammatory myopathies: a case-report and review of the literature. Clin Exp Rheumatol. 2012;30:979. PubMed  Google Scholar  * Liang J, Zhang H, Kong W, Deng W, Wang D, Feng X,

et al. Safety analysis in patients with autoimmune disease receiving allogeneic mesenchymal stem cells infusion: a long-term retrospective study. Stem Cell Res Ther. 2018;9:312. PubMed 

PubMed Central  Google Scholar  * Bourin P, Bunnell BA, Casteilla L, Dominici M, Katz AJ, March KL, et al. Stromal cells from the adipose tissue-derived stromal vascular fraction and culture

expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular

Therapy (ISCT). Cytotherapy. 2013;15:641–8. PubMed  PubMed Central  Google Scholar  * Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose

tissue: implications for cell-based therapies. Tissue Eng. 2001;7:211–28. CAS  PubMed  Google Scholar  * Bora P, Majumdar AS. Adipose tissue-derived stromal vascular fraction in regenerative

medicine: a brief review on biology and translation. Stem Cell Res Ther. 2017;8:145. PubMed  PubMed Central  Google Scholar  * Howard EE, Pasiakos SM, Blesso CN, Fussell MA, Rodriguez NR.

Divergent roles of inflammation in skeletal muscle recovery from injury. Front Physiol. 2020;11:87. PubMed  PubMed Central  Google Scholar  * Bianchi ME, Manfredi AA. High-mobility group box

1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007;220:35–46. CAS  PubMed  Google Scholar  * Gorospe JR, Nishikawa BK, Hoffman EP. Recruitment of

mast cells to muscle after mild damage. J Neurol Sci. 1996;135:10–17. CAS  PubMed  Google Scholar  * Fielding RA, Manfredi TJ, Ding W, Fiatarone MA, Evans WJ, Cannon JG. Acute phase response

in exercise. III. Neutrophil and IL-1 beta accumulation in skeletal muscle. Am J Physiol. 1993;265:R166–72. CAS  PubMed  Google Scholar  * Butterfield TA, Best TM, Merrick MA. The dual

roles of neutrophils and macrophages in inflammation: a critical balance between tissue damage and repair. J Athl Train. 2006;41:457–65. PubMed  PubMed Central  Google Scholar  * Arango

Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol. 2014;5:491. PubMed  PubMed Central  Google Scholar  * Cheng M, Nguyen M-H,

Fantuzzi G, Koh TJ. Endogenous interferon-gamma is required for efficient skeletal muscle regeneration. Am J Physiol Cell Physiol. 2008;294:C1183–91. CAS  PubMed  Google Scholar  * Zhang J,

Xiao Z, Qu C, Cui W, Wang X, Du J. CD8 T cells are involved in skeletal muscle regeneration through facilitating MCP-1 secretion and Gr1(high) macrophage infiltration. J Immunol.

2014;193:5149–60. CAS  PubMed  Google Scholar  * Madaro L, Bouché M. From innate to adaptive immune response in muscular dystrophies and skeletal muscle regeneration: the role of

lymphocytes. BioMed Res Int. 2014;2014:438675. PubMed  PubMed Central  Google Scholar  * Fu X, Xiao J, Wei Y, Li S, Liu Y, Yin J, et al. Combination of inflammation-related cytokines

promotes long-term muscle stem cell expansion. Cell Res. 2015;25:655–73. CAS  PubMed  PubMed Central  Google Scholar  * Peterson JM, Bakkar N, Guttridge DC. NF-κB signaling in skeletal

muscle health and disease. Curr Top Dev Biol. 2011;96:85–119. CAS  PubMed  Google Scholar  * Chen S-E, Jin B, Li Y-P. TNF-alpha regulates myogenesis and muscle regeneration by activating p38

MAPK. Am J Physiol Cell Physiol. 2007;292:C1660–71. CAS  PubMed  Google Scholar  * Chen S-E, Gerken E, Zhang Y, Zhan M, Mohan RK, Li AS, et al. Role of TNF-{alpha} signaling in regeneration

of cardiotoxin-injured muscle. Am J Physiol Cell Physiol. 2005;289:C1179–87. CAS  PubMed  Google Scholar  * Warren GL, Hulderman T, Jensen N, McKinstry M, Mishra M, Luster MI, et al.

Physiological role of tumor necrosis factor alpha in traumatic muscle injury. FASEB J. 2002;16:1630–2. CAS  PubMed  Google Scholar  * Muñoz-Cánoves P, Scheele C, Pedersen BK, Serrano AL.

Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword? FEBS J. 2013;280:4131–48. PubMed  PubMed Central  Google Scholar  * Chaweewannakorn C, Tsuchiya M, Koide M,

Hatakeyama H, Tanaka Y, Yoshida S, et al. Roles of IL-1α/β in regeneration of cardiotoxin-injured muscle and satellite cell function. Am J Physiol Regul Integr Comp Physiol.

2018;315:R90–103. CAS  PubMed  Google Scholar  * Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23–35. CAS  PubMed  Google Scholar  * Heredia JE, Mukundan L, Chen

FM, Mueller AA, Deo RC, Locksley RM, et al. Type 2 innate signals stimulate fibro/adipogenic progenitors to facilitate muscle regeneration. Cell. 2013;153:376–88. CAS  PubMed  PubMed Central

  Google Scholar  * Sciorati C, Rigamonti E, Manfredi AA, Rovere-Querini P. Cell death, clearance and immunity in the skeletal muscle. Cell Death Differ. 2016;23:927–37. CAS  PubMed  PubMed

Central  Google Scholar  * Otto A, Schmidt C, Luke G, Allen S, Valasek P, Muntoni F, et al. Canonical Wnt signalling induces satellite-cell proliferation during adult skeletal muscle

regeneration. J Cell Sci. 2008;121:2939–50. CAS  PubMed  Google Scholar  * Serrano AL, Baeza-Raja B, Perdiguero E, Jardí M, Muñoz-Cánoves P. Interleukin-6 is an essential regulator of

satellite cell-mediated skeletal muscle hypertrophy. Cell Metab. 2008;7:33–44. CAS  PubMed  Google Scholar  * Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A

special population of regulatory T cells potentiates muscle repair. Cell. 2013;155:1282–95. CAS  PubMed  PubMed Central  Google Scholar  * Kuswanto W, Burzyn D, Panduro M, Wang KK, Jang YC,

Wagers AJ, et al. Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent, accumulation of regulatory T cells. Immunity. 2016;44:355–67. CAS  PubMed

  PubMed Central  Google Scholar  * Wu J, Ren B, Wang D, Lin H. Regulatory T cells in skeletal muscle repair and regeneration: recent insights. Cell Death Dis. 2022;13:680. PubMed  PubMed

Central  Google Scholar  * Stout RD, Suttles J. Functional plasticity of macrophages: reversible adaptation to changing microenvironments. J Leukoc Biol. 2004;76:509–13. CAS  PubMed  Google

Scholar  * Ruffell D, Mourkioti F, Gambardella A, Kirstetter P, Lopez RG, Rosenthal N, et al. A CREB-C/EBPbeta cascade induces M2 macrophage-specific gene expression and promotes muscle

injury repair. Proc Natl Acad Sci USA. 2009;106:17475–80. CAS  PubMed  PubMed Central  Google Scholar  * Lemos DR, Babaeijandaghi F, Low M, Chang C-K, Lee ST, Fiore D, et al. Nilotinib

reduces muscle fibrosis in chronic muscle injury by promoting TNF-mediated apoptosis of fibro/adipogenic progenitors. Nat Med. 2015;21:786–94. CAS  PubMed  Google Scholar  * Pillon NJ, Bilan

PJ, Fink LN, Klip A. Cross-talk between skeletal muscle and immune cells: muscle-derived mediators and metabolic implications. Am J Physiol Endocrinol Metab. 2013;304:E453–65. CAS  PubMed 

Google Scholar  * Christov C, Chrétien F, Abou-Khalil R, Bassez G, Vallet G, Authier F-J, et al. Muscle satellite cells and endothelial cells: close neighbors and privileged partners. Mol

Biol Cell. 2007;18:1397–409. CAS  PubMed  PubMed Central  Google Scholar  * Fang J, Feng C, Chen W, Hou P, Liu Z, Zuo M, et al. Redressing the interactions between stem cells and immune

system in tissue regeneration. Biol Direct. 2021;16:18. CAS  PubMed  PubMed Central  Google Scholar  * Seto N, Torres-Ruiz JJ, Carmona-Rivera C, Pinal-Fernandez I, Pak K, Purmalek MM, et al.

Neutrophil dysregulation is pathogenic in idiopathic inflammatory myopathies. JCI Insight. 2020;5:e134189. PubMed  PubMed Central  Google Scholar  * Gao S, Zuo X, Liu D, Xiao Y, Zhu H,

Zhang H, et al. The roles of neutrophil serine proteinases in idiopathic inflammatory myopathies. Arthritis Res Ther. 2018;20:134. PubMed  PubMed Central  Google Scholar  * Reimann J,

Schnell S, Schwartz S, Kappes-Horn K, Dodel R, Bacher M. Macrophage migration inhibitory factor in normal human skeletal muscle and inflammatory myopathies. J Neuropathol Exp Neurol.

2010;69:654–62. CAS  PubMed  Google Scholar  * Preuße C, Goebel HH, Held J, Wengert O, Scheibe F, Irlbacher K, et al. Immune-mediated necrotizing myopathy is characterized by a specific

Th1-M1 polarized immune profile. Am J Pathol. 2012;181:2161–71. PubMed  Google Scholar  * Allenbach Y, Chaara W, Rosenzwajg M, Six A, Prevel N, Mingozzi F, et al. Th1 response and systemic

treg deficiency in inclusion body myositis. PLoS ONE. 2014;9:e88788. PubMed  PubMed Central  Google Scholar  * Moran EM, Mastaglia FL. Cytokines in immune-mediated inflammatory myopathies:

cellular sources, multiple actions and therapeutic implications. Clin Exp Immunol. 2014;178:405–15. CAS  PubMed  PubMed Central  Google Scholar  * Greenberg SA, Higgs BW, Morehouse C, Walsh

RJ, Kong SW, Brohawn P, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes

Immun. 2012;13:207–13. CAS  PubMed  Google Scholar  * Ladislau L, Suárez-Calvet X, Toquet S, Landon-Cardinal O, Amelin D, Depp M, et al. JAK inhibitor improves type I interferon induced

damage: proof of concept in dermatomyositis. Brain J Neurol. 2018;141:1609–21. Google Scholar  * Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin-17

increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003;137:125–33. CAS  PubMed  Google Scholar  * Fréret

M, Drouot L, Obry A, Ahmed-Lacheheb S, Dauly C, Adriouch S, et al. Overexpression of MHC class I in muscle of lymphocyte-deficient mice causes a severe myopathy with induction of the

unfolded protein response. Am J Pathol. 2013;183:893–904. PubMed  Google Scholar  * Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, et al. Activation of the

endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheumatol. 2005;52:1824–35. CAS  Google Scholar  * Page G,

Chevrel G, Miossec P. Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells.

Arthritis Rheumatol. 2004;50:199–208. CAS  Google Scholar  * Wang S, Wang H, Feng C, Li C, Li Z, He J, et al. The regulatory role and therapeutic application of pyroptosis in musculoskeletal

diseases. Cell Death Discov. 2022;8:492. CAS  PubMed  PubMed Central  Google Scholar  * Salajegheh M, Pinkus JL, Amato AA, Morehouse C, Jallal B, Yao Y, et al. Permissive environment for

B-cell maturation in myositis muscle in the absence of B-cell follicles. Muscle Nerve. 2010;42:576–83. PubMed  Google Scholar  * Radke J, Koll R, Preuße C, Pehl D, Todorova K, Schönemann C,

et al. Architectural B-cell organization in skeletal muscle identifies subtypes of dermatomyositis. Neurol Neuroimmunol Neuroinflamm. 2018;5:e451. PubMed  PubMed Central  Google Scholar  *

Stuhlmüller B, Schneider U, González-González J-B, Feist E. Disease specific autoantibodies in idiopathic inflammatory myopathies. Front Neurol. 2019;10:438. PubMed  PubMed Central  Google

Scholar  * Arouche-Delaperche L, Allenbach Y, Amelin D, Preusse C, Mouly V, Mauhin W, et al. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA

reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol. 2017;81:538–48. CAS  PubMed  Google

Scholar  * Bergua C, Chiavelli H, Allenbach Y, Arouche-Delaperche L, Arnoult C, Bourdenet G, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in

immune-mediated necrotising myopathy. Ann Rheum Dis. 2019;78:131–9. CAS  PubMed  Google Scholar  * Fujiyama T, Ito T, Ogawa N, Suda T, Tokura Y, Hashizume H. Preferential infiltration of

interleukin-4-producing CXCR4+ T cells in the lesional muscle but not skin of patients with dermatomyositis. Clin Exp Immunol. 2014;177:110–20. CAS  PubMed  PubMed Central  Google Scholar  *

Rostasy KM, Schmidt J, Bahn E, Pfander T, Piepkorn M, Wilichowski E, et al. Distinct inflammatory properties of late-activated macrophages in inflammatory myopathies. Acta Myol.

2008;27:49–53. CAS  PubMed  PubMed Central  Google Scholar  * Noda S, Koike H, Maeshima S, Nakanishi H, Iijima M, Matsuo K, et al. Transforming growth factor-β signaling is upregulated in

sporadic inclusion body myositis. Muscle Nerve. 2017;55:741–7. CAS  PubMed  Google Scholar  * Burks TN, Cohn RD. Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle.

2011;1:19. CAS  PubMed  PubMed Central  Google Scholar  * Confalonieri P, Bernasconi P, Cornelio F, Mantegazza R. Transforming growth factor-beta 1 in polymyositis and dermatomyositis

correlates with fibrosis but not with mononuclear cell infiltrate. J Neuropathol Exp Neurol. 1997;56:479–84. CAS  PubMed  Google Scholar  * Girardi F, Taleb A, Ebrahimi M, Datye A, Gamage

DG, Peccate C, et al. TGFβ signaling curbs cell fusion and muscle regeneration. Nat Commun. 2021;12:750. CAS  PubMed  PubMed Central  Google Scholar  * Uezumi A, Ito T, Morikawa D, Shimizu

N, Yoneda T, Segawa M, et al. Fibrosis and adipogenesis originate from a common mesenchymal progenitor in skeletal muscle. J Cell Sci. 2011;124:3654–64. CAS  PubMed  Google Scholar  * Saito

Y, Chikenji TS, Matsumura T, Nakano M, Fujimiya M. Exercise enhances skeletal muscle regeneration by promoting senescence in fibro-adipogenic progenitors. Nat Commun. 2020;11:889. CAS 

PubMed  PubMed Central  Google Scholar  * Wanschitz JV, Dubourg O, Lacene E, Fischer MB, Höftberger R, Budka H, et al. Expression of myogenic regulatory factors and myo-endothelial

remodeling in sporadic inclusion body myositis. Neuromuscul Disord. 2013;23:75–83. PubMed  PubMed Central  Google Scholar  * Schiaffino S, Pereira MG, Ciciliot S, Rovere-Querini P.

Regulatory T cells and skeletal muscle regeneration. FEBS J. 2017;284:517–24. CAS  PubMed  Google Scholar  * Henriques-Pons A, Nagaraju K. Nonimmune mechanisms of muscle damage in myositis:

role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis. Curr Opin Rheumatol. 2009;21:581–7. PubMed  PubMed Central  Google Scholar  * Benveniste O,

Stenzel W, Hilton-Jones D, Sandri M, Boyer O, van Engelen BGM. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the

degenerative chicken. Acta Neuropathol. 2015;129:611–24. CAS  PubMed  PubMed Central  Google Scholar  * Loell I, Lundberg IE. Can muscle regeneration fail in chronic inflammation: a weakness

in inflammatory myopathies? J Intern Med. 2011;269:243–57. CAS  PubMed  Google Scholar  * Morosetti R, Broccolini A, Sancricca C, Gliubizzi C, Gidaro T, Tonali PA, et al. Increased aging in

primary muscle cultures of sporadic inclusion-body myositis. Neurobiol Aging. 2010;31:1205–14. PubMed  Google Scholar  * Barsotti S, Lundberg IE. Current treatment for myositis. Curr Treat

Options Rheumatol. 2018;4:299–315. Google Scholar  * Schakman O, Kalista S, Barbé C, Loumaye A, Thissen JP. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol.

2013;45:2163–72. CAS  PubMed  Google Scholar  * Ponticelli C, Glassock RJ. Prevention of complications from use of conventional immunosuppressants: a critical review. J Nephrol.

2019;32:851–70. PubMed  Google Scholar  * Khoo T, Limaye V. Biologic therapy in the idiopathic inflammatory myopathies. Rheumatol Int. 2020;40:191–205. PubMed  Google Scholar  * Paik JJ,

Casciola-Rosen L, Shin JY, Albayda J, Tiniakou E, Leung DG, et al. Study of tofacitinib in refractory dermatomyositis (STIR): an open label pilot study of 10 patients. Arthritis Rheumatol.

2020. https://doi.org/10.1002/art.41602. * Julien S, Vadysirisack D, Sayegh C, Ragunathan S, Tang Y, Briand E, et al. Prevention of anti-HMGCR immune-mediated necrotising myopathy by C5

complement inhibition in a humanised mouse model. Biomedicines. 2022;10:2036. CAS  PubMed  PubMed Central  Google Scholar  * Mammen AL, Amato AA, Dimachkie MM, Chinoy H, Hussain Y, Lilleker

JB, et al. Zilucoplan in immune-mediated necrotising myopathy: a phase 2, randomised, double-blind, placebo-controlled, multicentre trial. Lancet Rheumatol. 2023;5:e67–76. CAS  PubMed 

Google Scholar  * Schmidt K, Schmidt J. Inclusion body myositis: advancements in diagnosis, pathomechanisms, and treatment. Curr Opin Rheumatol. 2017;29:632–8. PubMed  Google Scholar  * Dao

T, Green AE, Kim YA, Bae S-J, Ha K-T, Gariani K, et al. Sarcopenia and muscle aging: a brief overview. Endocrinol Metab. 2020;35:716–32. CAS  Google Scholar  * Bohan A, Peter JB.

Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292:403–7. CAS  PubMed  Google Scholar  * Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X, et al. Efficacy of

allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70:1285–8. PubMed  Google Scholar  * Lai Q, Yu L, Qiu

Y, Chen L, Huang J, Li Y, et al. Umbilical cord blood mesenchymal stem cells transplantion for polymyositis/dermatomyositis:variation of Th cytokines. Chin J Tissue Eng Res. 2015;14:2186–91.

Google Scholar  * Ra JC, Kang SK, Shin IS, Park HG, Joo SA, Kim JG, et al. Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous

adipose tissue derived mesenchymal stem cells. J Transl Med. 2011;9:181. PubMed  PubMed Central  Google Scholar  * Senesi L, De Francesco F, Farinelli L, Manzotti S, Gagliardi G, Papalia GF,

et al. Mechanical and enzymatic procedures to isolate the stromal vascular fraction from adipose tissue: preliminary results. Front Cell Dev Biol. 2019;7:88. PubMed  PubMed Central  Google

Scholar  * Condé-Green A, Kotamarti VS, Sherman LS, Keith JD, Lee ES, Granick MS, et al. Shift toward mechanical isolation of adipose-derived stromal vascular fraction: review of upcoming

techniques. Plast Reconstr Surg Glob Open. 2016;4:e1017. PubMed  PubMed Central  Google Scholar  * van Dongen JA, Tuin AJ, Spiekman M, Jansma J, van der Lei B, Harmsen MC. Comparison of

intraoperative procedures for isolation of clinical grade stromal vascular fraction for regenerative purposes: a systematic review. J Tissue Eng Regen Med. 2018;12:e261–74. PubMed  Google

Scholar  * Yao Y, Dong Z, Liao Y, Zhang P, Ma J, Gao J, et al. Adipose extracellular matrix/stromal vascular fraction gel: a novel adipose tissue-derived injectable for stem cell therapy.

Plast Reconstr Surg. 2017;139:867–79. CAS  PubMed  Google Scholar  * Laschke MW, Menger MD. Adipose tissue-derived microvascular fragments: natural vascularization units for regenerative

medicine. Trends Biotechnol. 2015;33:442–8. CAS  PubMed  Google Scholar  * Toyserkani NM, Jørgensen MG, Tabatabaeifar S, Jensen CH, Sheikh SP, Sørensen JA. Concise review: a safety

assessment of adipose-derived cell therapy in clinical trials: a systematic review of reported adverse events. Stem Cells Transl Med. 2017;6:1786–94. PubMed  PubMed Central  Google Scholar 

* Murdoch B, Zarzeczny A, Caulfield T. Exploiting science? A systematic analysis of complementary and alternative medicine clinic websites’ marketing of stem cell therapies. BMJ Open.

2018;8:e019414. PubMed  PubMed Central  Google Scholar  * Knoepfler PS. Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years. Regen Med. 2019;14:735–40. CAS 

PubMed  Google Scholar  * Commissioner, O of the. Innovative regenerative medicine therapies – patient safety comes first. FDA_._ 2021.

https://www.fda.gov/news-events/fda-voices/innovative-regenerative-medicine-therapies-patient-safety-comes-first. * Andia I, Maffulli N, Burgos-Alonso N. Stromal vascular fraction

technologies and clinical applications. Expert Opin Biol Ther. 2019;19:1289–305. PubMed  Google Scholar  * Bauer G, Elsallab M, Abou-El-Enein M. Concise review: a comprehensive analysis of

reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med. 2018;7:676–85. PubMed  PubMed Central  Google Scholar  * Pritchett JW. The debit

side of stem-cell joint injections: a prospective cohort study. Curr Orthop Pract. 2021;32:118–23. Google Scholar  * Ge J, Guo L, Wang S, Zhang Y, Cai T, Zhao RCH, et al. The size of

mesenchymal stem cells is a significant cause of vascular obstructions and stroke. Stem Cell Rev Rep. 2014;10:295–303. CAS  PubMed  Google Scholar  * Monreal J. Functional and aesthetic

recovery of congenital muscular torticollis with intramuscular stromal vascular fraction enriched fat grafting. Cureus. 2017;9:e975. PubMed  PubMed Central  Google Scholar  * Lee H-B, Park

S-W, Kim J, Hwang K-C, Kim I-K, Sun H-M, et al. Intramuscular injection of adipose tissue derived stromal vascular fraction in subjects with poliomyelitis: case reports. Int J Stem Cell Res

Ther. 2019;1:20–27. Google Scholar  * Bura A, Planat-Benard V, Bourin P, Silvestre J-S, Gross F, Grolleau J-L, et al. Phase I trial: the use of autologous cultured adipose-derived

stroma/stem cells to treat patients with non-revascularizable critical limb ischemia. Cytotherapy. 2014;16:245–57. CAS  PubMed  Google Scholar  * Lee HC, An SG, Lee HW, Park J-S, Cha KS,

Hong TJ, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ J J Jpn Circ Soc. 2012;76:1750–60. CAS  Google

Scholar  * Hamidian Jahromi S, Davies JE. Concise review: skeletal muscle as a delivery route for mesenchymal stromal cells. Stem Cells Transl Med. 2019;8:456–65. PubMed  PubMed Central 

Google Scholar  * Braid LR, Wood CA, Wiese DM, Ford BN. Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes. Cytotherapy.

2018;20:232–44. PubMed  Google Scholar  * Hamidian Jahromi S, Estrada C, Li Y, Cheng E, Davies JE. Human umbilical cord perivascular cells and human bone marrow mesenchymal stromal cells

transplanted intramuscularly respond to a distant source of inflammation. Stem Cells Dev. 2018;27:415–29. CAS  PubMed  Google Scholar  * Puissant B, Barreau C, Bourin P, Clavel C, Corre J,

Bousquet C, et al. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol. 2005;129:118–29. PubMed 

Google Scholar  * Najar M, Raicevic G, Fayyad-Kazan H, De Bruyn C, Bron D, Toungouz M, et al. Impact of different mesenchymal stromal cell types on T-cell activation, proliferation and

migration. Int Immunopharmacol. 2013;15:693–702. CAS  PubMed  Google Scholar  * Ketterl N, Brachtl G, Schuh C, Bieback K, Schallmoser K, Reinisch A, et al. A robust potency assay highlights

significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. Stem Cell Res Ther. 2015;6:236. PubMed  PubMed Central  Google

Scholar  * Bowles AC, Strong AL, Wise RM, Thomas RC, Gerstein BY, Dutreil MF, et al. Adipose stromal vascular fraction-mediated improvements at late-stage disease in a murine model of

multiple sclerosis. Stem Cells. 2017;35:532–44. CAS  PubMed  Google Scholar  * Cui L, Yin S, Liu W, Li N, Zhang W, Cao Y. Expanded adipose-derived stem cells suppress mixed lymphocyte

reaction by secretion of prostaglandin E2. Tissue Eng. 2007;13:1185–95. CAS  PubMed  Google Scholar  * DelaRosa O, Lombardo E, Beraza A, Mancheño-Corvo P, Ramirez C, Menta R, et al.

Requirement of IFN-gamma-mediated indoleamine 2,3-dioxygenase expression in the modulation of lymphocyte proliferation by human adipose-derived stem cells. Tissue Eng Part A.

2009;15:2795–806. CAS  PubMed  Google Scholar  * Menta R, Mancheño-Corvo P, Del Río B, Ramírez C, DelaRosa O, Dalemans W, et al. Tryptophan concentration is the main mediator of the capacity

of adipose mesenchymal stromal cells to inhibit T-lymphocyte proliferation in vitro. Cytotherapy. 2014;16:1679–91. CAS  PubMed  Google Scholar  * Najar M, Raicevic G, Fayyad-Kazan H, De

Bruyn C, Bron D, Toungouz M, et al. Bone marrow mesenchymal stromal cells induce proliferative, cytokinic and molecular changes during the T cell response: the importance of the IL-10/CD210

axis. Stem Cell Rev Rep. 2015;11:442–52. CAS  PubMed  Google Scholar  * Cho K-S, Park M-K, Kang S-A, Park H-Y, Hong S-L, Park H-K, et al. Adipose-derived stem cells ameliorate allergic

airway inflammation by inducing regulatory T cells in a mouse model of asthma. Mediators Inflamm. 2014;2014:436476. PubMed  PubMed Central  Google Scholar  * Zeng Q, Sun X, Xiao L, Xie Z,

Bettini M, Deng T. A unique population: adipose-resident regulatory T cells. Front Immunol. 2018;9:2075. PubMed  PubMed Central  Google Scholar  * Németh K, Leelahavanichkul A, Yuen PST,

Mayer B, Parmelee A, Doi K, et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.

Nat Med. 2009;15:42–9. PubMed  Google Scholar  * Shi J, Lu P, Shen W, He R, Yang M-W, Fang Y, et al. CD90 highly expressed population harbors a stemness signature and creates an

immunosuppressive niche in pancreatic cancer. Cancer Lett. 2019;453:158–69. PubMed  Google Scholar  * Ménard C, Dulong J, Roulois D, Hébraud B, Verdière L, Pangault C, et al. Integrated

transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells. 2020;38:146–59. PubMed  Google Scholar  * Espagnolle N,

Balguerie A, Arnaud E, Sensebé L, Varin A. CD54-mediated interaction with pro-inflammatory macrophages increases the immunosuppressive function of human mesenchymal stromal cells. Stem Cell

Rep. 2017;8:961–76. CAS  Google Scholar  * Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84.

CAS  PubMed  PubMed Central  Google Scholar  * Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory

effects of IL-10 in human macrophages. J Immunol. 2004;172:567–76. CAS  PubMed  Google Scholar  * Hutchins AP, Diez D, Miranda-Saavedra D. The IL-10/STAT3-mediated anti-inflammatory

response: recent developments and future challenges. Brief Funct Genom. 2013;12:489–98. CAS  Google Scholar  * Murray PJ. The primary mechanism of the IL-10-regulated antiinflammatory

response is to selectively inhibit transcription. Proc Natl Acad Sci USA. 2005;102:8686–91. CAS  PubMed  PubMed Central  Google Scholar  * Sato Y, Ohshima T, Kondo T. Regulatory role of

endogenous interleukin-10 in cutaneous inflammatory response of murine wound healing. Biochem Biophys Res Commun. 1999;265:194–9. CAS  PubMed  Google Scholar  * Shi J-H, Guan H, Shi S, Cai

W-X, Bai X-Z, Hu X-L, et al. Protection against TGF-β1-induced fibrosis effects of IL-10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring. Arch

Dermatol Res. 2013;305:341–52. CAS  PubMed  Google Scholar  * Shi J, Li J, Guan H, Cai W, Bai X, Fang X, et al. Anti-fibrotic actions of interleukin-10 against hypertrophic scarring by

activation of PI3K/AKT and STAT3 signaling pathways in scar-forming fibroblasts. PLoS ONE. 2014;9:e98228. PubMed  PubMed Central  Google Scholar  * Serratrice N, Bruzzese L, Magalon J, Véran

J, Giraudo L, Aboudou H, et al. New fat-derived products for treating skin-induced lesions of scleroderma in nude mice. Stem Cell Res Ther. 2014;5:138. PubMed  PubMed Central  Google

Scholar  * Mattei A, Magalon J, Bertrand B, Grimaud F, Revis J, Velier M, et al. Autologous adipose-derived stromal vascular fraction and scarred vocal folds: first clinical case report.

Stem Cell Res Ther. 2018;9:202. PubMed  PubMed Central  Google Scholar  * Domergue S, Bony C, Maumus M, Toupet K, Frouin E, Rigau V, et al. Comparison between stromal vascular fraction and

adipose mesenchymal stem cells in remodeling hypertrophic scars. PLoS ONE. 2016;11:e0156161. PubMed  PubMed Central  Google Scholar  * Usunier B, Benderitter M, Tamarat R, Chapel A.

Management of fibrosis: the mesenchymal stromal cells breakthrough. Stem Cells Int. 2014;2014:340257. PubMed  PubMed Central  Google Scholar  * Burbridge MF, Cogé F, Galizzi JP, Boutin JA,

West DC, Tucker GC. The role of the matrix metalloproteinases during in vitro vessel formation. Angiogenesis. 2002;5:215–26. CAS  PubMed  Google Scholar  * Jin E, Chae D-S, Son M, Kim S-W.

Angiogenic characteristics of human stromal vascular fraction in ischemic hindlimb. Int J Cardiol. 2017;234:38–47. PubMed  Google Scholar  * Planat-Benard V, Silvestre J-S, Cousin B, André

M, Nibbelink M, Tamarat R, et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation. 2004;109:656–63. PubMed  Google

Scholar  * Traktuev DO, Merfeld-Clauss S, Li J, Kolonin M, Arap W, Pasqualini R, et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal

surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res. 2008;102:77–85. CAS  PubMed  Google Scholar  * Traktuev DO, Prater DN, Merfeld-Clauss S,

Sanjeevaiah AR, Saadatzadeh MR, Murphy M, et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. Circ Res. 2009;104:1410–20.

CAS  PubMed  Google Scholar  * Hellström M, Kalén M, Lindahl P, Abramsson A, Betsholtz C. Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during

embryonic blood vessel formation in the mouse. Development. 1999;126:3047–55. PubMed  Google Scholar  * Lopatina T, Bruno S, Tetta C, Kalinina N, Porta M, Camussi G. Platelet-derived growth

factor regulates the secretion of extracellular vesicles by adipose mesenchymal stem cells and enhances their angiogenic potential. Cell Commun Signal. 2014;12:26. PubMed  PubMed Central 

Google Scholar  * Zhou L, Xia J, Qiu X, Wang P, Jia R, Chen Y, et al. In vitro evaluation of endothelial progenitor cells from adipose tissue as potential angiogenic cell sources for bladder

angiogenesis. PLoS ONE. 2015;10:e0117644. PubMed  PubMed Central  Google Scholar  * Matsui J, Wakabayashi T, Asada M, Yoshimatsu K, Okada M. Stem cell factor/c-kit signaling promotes the

survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem. 2004;279:18600–7. CAS  PubMed  Google Scholar  * Stapor PC, Sweat RS, Dashti DC,

Betancourt AM, Murfee WL. Pericyte dynamics during angiogenesis: new insights from new identities. J Vasc Res. 2014;51:163–74. PubMed  Google Scholar  * Lindahl P, Johansson BR, Levéen P,

Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science. 1997;277:242–5. CAS  PubMed  Google Scholar  * Ascenzi F, Barberi L, Dobrowolny G, Villa Nova

Bacurau A, Nicoletti C, Rizzuto E, et al. Effects of IGF-1 isoforms on muscle growth and sarcopenia. Aging Cell. 2019;18:e12954. PubMed  PubMed Central  Google Scholar  * Lee J-H, Kemp DM.

Human adipose-derived stem cells display myogenic potential and perturbed function in hypoxic conditions. Biochem Biophys Res Commun. 2006;341:882–8. CAS  PubMed  Google Scholar  * Mizuno H,

Zuk PA, Zhu M, Lorenz HP, Benhaim P, Hedrick MH. Myogenic differentiation by human processed lipoaspirate cells. Plast Reconstr Surg .2002;109:199–209. PubMed  Google Scholar  * Goudenege

S, Pisani DF, Wdziekonski B, Di Santo JP, Bagnis C, Dani C, et al. Enhancement of myogenic and muscle repair capacities of human adipose-derived stem cells with forced expression of MyoD.

Mol Ther J Am Soc Gene Ther. 2009;17:1064–72. CAS  Google Scholar  * Di Rocco G, Iachininoto MG, Tritarelli A, Straino S, Zacheo A, Germani A, et al. Myogenic potential of

adipose-tissue-derived cells. J Cell Sci. 2006;119:2945–52. PubMed  Google Scholar  * Bacou F, Andalousi RBE, Daussin P-A, Micallef J-P, Levin JM, Chammas M, et al. Transplantation of

adipose tissue-derived stromal cells increases mass and functional capacity of damaged skeletal muscle. Cell Transpl. 2004;13:103–11. Google Scholar  * Zimowska M, Archacka K, Brzoska E, Bem

J, Czerwinska AM, Grabowska I, et al. IL-4 and SDF-1 increase adipose tissue-derived stromal cell ability to improve rat skeletal muscle regeneration. Int J Mol Sci. 2020;21:3302. CAS 

PubMed  PubMed Central  Google Scholar  * Rodriguez A-M, Pisani D, Dechesne CA, Turc-Carel C, Kurzenne J-Y, Wdziekonski B, et al. Transplantation of a multipotent cell population from human

adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. J Exp Med. 2005;201:1397–405. CAS  PubMed  PubMed Central  Google Scholar  Download references ACKNOWLEDGEMENTS

This work was supported by the Fondation pour la Recherche Médicale (grant # FDM201806006523). The authors are grateful to Nikki Sabourin-Gibbs, Rouen University Hospital, for her help in

editing the manuscript. AUTHOR INFORMATION Author notes * These authors contributed equally: S. Gandolfi, B. Pileyre. AUTHORS AND AFFILIATIONS * Univ Rouen Normandie, INSERM U1234, FOCIS

Center of Excellence PAn’THER, F-76000, Rouen, France S. Gandolfi, B. Pileyre, L. Drouot & I. Dubus * Toulouse University Hospital, Department of Plastic and Reconstructive Surgery,

F-31000, Toulouse, France S. Gandolfi * Centre Henri Becquerel, Department of Pharmacy, F-76000, Rouen, France B. Pileyre * Univ Rouen Normandie, INSERM U1234, FOCIS Center of Excellence

PAn’THER, CHU Rouen, Department of Plastic, Reconstructive and Hand Surgery, F-76000, Rouen, France I. Auquit-Auckbur * Univ Rouen Normandie, INSERM U1234, FOCIS Center of Excellence

PAn’THER, CHU Rouen, Department of Immunology and Biotherapy, F-76000, Rouen, France J. Martinet Authors * S. Gandolfi View author publications You can also search for this author inPubMed 

Google Scholar * B. Pileyre View author publications You can also search for this author inPubMed Google Scholar * L. Drouot View author publications You can also search for this author

inPubMed Google Scholar * I. Dubus View author publications You can also search for this author inPubMed Google Scholar * I. Auquit-Auckbur View author publications You can also search for

this author inPubMed Google Scholar * J. Martinet View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS SG and BP were the manuscript’s principal

authors. LD, ID, IA, and JM participated in manuscript writing and editing. All authors approved the final manuscript. CORRESPONDING AUTHOR Correspondence to B. Pileyre. ETHICS DECLARATIONS

COMPETING INTERESTS The authors declare no competing interests. ADDITIONAL INFORMATION PUBLISHER’S NOTE Springer Nature remains neutral with regard to jurisdictional claims in published

maps and institutional affiliations. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing,

adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons

license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a

credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted

use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT

THIS ARTICLE CITE THIS ARTICLE Gandolfi, S., Pileyre, B., Drouot, L. _et al._ Stromal vascular fraction in the treatment of myositis. _Cell Death Discov._ 9, 346 (2023).

https://doi.org/10.1038/s41420-023-01605-9 Download citation * Received: 13 March 2023 * Revised: 01 August 2023 * Accepted: 14 August 2023 * Published: 19 September 2023 * DOI:

https://doi.org/10.1038/s41420-023-01605-9 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link Sorry, a shareable link is not

currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative